PARProceedings of Anticancer Research2208-35452208-3553Bio-Byword Scientific Publishing Pty. Ltd.10.26689/par.v7i3.4850ArticlePerformance Evaluation of Combined Detection of Serum CEA, CYFRA21-1, CA125, and NSE in Patients with Lung Cancer by Fluorescence Flow Cytometryhttps://artdesignp.com/journal/PAR/7/3/10.26689/par.v7i3.4850HuangXiaoxue,ZhengXiaomeng,LiYiyang,DuanLin,YuYang2023732023-05-30Objective: To investigate the effect of combined detection of serum carcinoembryonic antigen (CEA), cytokeratin 19 fragment (CYFRA21-1), cancer antigen 125 (CA125), and neuron-specific enolase (NSE) in patients with lung cancer by fluorescence flow cytometry. Methods: From August 2019 to July 2022, 200 patients with lung cancer diagnosed by pathology in our hospital were retrospectively analyzed. 2 mL venous blood was collected in a fasting state and centrifuged to separate the serum (containing human chorionic gonadotropin antibody [anti-hCG antibody], hepatitis B surface antibody [anti-HBs antibody], and CEA). Results: The sensitivities of CEA and CYFRA21-1 detected via enzyme-linked immunosorbent assay (ELISA) were 100%, and the detection limits were 0.5 ng/mL and 0.1 ng/mL, respectively; the sensitivities of CA125 and NSE detected via flow cytometry were 100%, and the detection limits were 10 U/mL and 2 ng/mL, respectively. Compared with ELISA, the sensitivities of CA125 and NSE detected via flow cytometry were higher. When the concentration of CEA was 10–40 ng/mL, the sensitivities of the three markers CYFRA21-1, CA125, and NSE showed no significant changes (P > 0.05); when the concentration of CEA was 40–80 ng/mL, the sensitivity of CEA significantly decreased (P < 0.01), but the sensitivities of the three markers CYFRA21-1, CA125, and NSE showed no significant changes (P > 0.05); when the concentration of CEA was 80–200 ng/mL, the sensitivities of all four markers showed no significant changes (P > 0.05). Conclusion: Compared with the double-antibody sandwich ELISA, fluorescence flow cytometry has certain advantages, including high sensitivity, good precision, short detection time, low sample usage, and low medical cost; thus, it is worthy of clinical promotion.

Yin Z, 2023, The Expression of Serum NSE and PCT in Patients with Lung Cancer and Their Impact on Postoperative Survival. Chinese Medical Innovation, 20(02): 26–31.

Jia C, Shen L, Sun Z, 2022, Relationship Between Changes in Serum CEA, CA125, NSE Levels and Pathological Characteristics of Patients with Non-Small Cell Lung Cancer and Analysis of Joint Detection Value. Clinical Metaphysics, 37(11): 992–995.

Xu C, 2021, The Value of Electrochemiluminescence and Flow Fluorescence Luminescence in the Detection of SCCA in the Auxiliary Diagnosis of Squamous Cell Carcinoma of Related Tissues. China Practical Medicine, 16(19): 61–63.

Wang N, Li X, Chen M, et al., 2021, The Application Value of Serum NSE, SCC, CA125 and CYFRA21-1 Level Detection in Patients with Lung Cancer in the Early Diagnosis of Different Pathological Types and the Evaluation of Chemotherapy Efficacy. Modern Laboratory Medicine Journal, 36(01): 33–37.

Guo J, Li D, Hu C, et al., 2020, Sensitivity and Specificity of Detection of serum CEA, CA19-9, CA125, CA153 and CYFRA21-1 in the Diagnosis of Lung Cancer Patients. Journal of Clinical and Pathology, 40(11): 2858–2863.

Li X, Zhu S, 2019, Effect of Serum CEACA125 and Cyfra21-1 Levels on the Prognosis of Patients with Advanced Non-Small Cell Lung Cancer. Hebei Medicine, 25(11): 1761–1764.

Tu X, 2019, Efficacy of Endostar Combined with Platinum-Based Chemotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer and Its Impact on Serum CEA, CYFRA21-1, CA125. Medical Theory and Practice, 32(19): 3108–3110.

Guo J, Hu C, Li D, et al., 2019, Clinical Study of Dynamic Monitoring of Serum CEA, CA19-9, CA125, CA153 and CYFRA21-1 on Perioperative Efficacy Evaluation of Lung Cancer Patients. Cancer Progress, 17(14): 1701–1703 + 1725.

Zhong W, 2018, Detection of Serum CEA, CA125, CYFRA21-1 and VEGF to Evaluate the Curative Effect of Radioactive 125I Implantation in Lung Cancer Patients. Labeled Immunoassay and Clinic, 25(07): 1029–1033.

Zhao H, Yao H, Zhang H, 2018, Comparative Analysis and Evaluation of the Results of Clinical Multi-Tumor Marker Samples by Flow Cytometry and Its Improved Technology. Chinese Experimental Diagnostics, 22(06): 1015 –1019.

Du J, Qiao H, Yin Y, 2016, Effects of Serum CEA, CA125 and Cyfra21-1 Levels on the Prognosis of Patients with Advanced Non-Small Cell Lung Cancer. Tumor Prevention and Treatment Research, 43(02): 137–140.

Li H, Gao T, 2014, Methodological Evaluation of Flow Cytometry for Detection of Multiple Tumor Markers. International Journal of Laboratory Medicine, 35(02): 203–204 + 207.

Xu Y, Wu C, Wu J, et al., 2012, Application of Flow Cytometry in the Detection of Serum cyfra21-1 in Patients with Lung Cancer. Journal of Clinical Testing, 30(12): 964–966.

Lei J, Liu L, Gao D, 2010, Study on Serum CEA, CYFRA21-1, CA125 Levels of Lung Cancer Patients Before and After Chemotherapy. Disease Surveillance and Control, 4(10): 577–578.

Liu D, Gao Y, Guo S, 2003, Clinical Significance of Detection of Serum CEA, CA125, and CYFRA21-1 in Patients with Lung Cancer. Journal of China Medical University, 2003(01): 96–97.